Hextend
Crohn's Disease
Corewell Health WestPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Crohn's Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE University of Saskatchewan | Phase 4 | BB |
Epinephrine Cedars-Sinai Medical Center | Phase 4 | BB |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Cedars-Sinai Medical Center | Phase 4 | BB |
Prucalopride University of British Columbia | Phase 4 | BB |
Oxygen Jay C. Buckey Jr. | Phase 4 | BB |
View all 20 →
Same molecule, other indications
Hextend is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →